PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2- advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial Meeting Abstract
| Authors: | Baselga, J.; Im, S. A.; Iwata, H.; Clemons, M.; Ito, Y.; Awada, A.; Chia, S.; Jagiello-Gruszfeld, A.; Pistilli, B.; Tseng, L. M.; Hurvitz, S.; Masuda, N.; Cortés, J.; De Laurentiis, M.; Arteaga, C. L.; Jiang, Z.; Jonat, W.; Hachemi, S.; Le Mouhaër, S.; Di Tomaso, E.; Urban, P.; Massacesi, C.; Campone, M. |
| Abstract Title: | PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2- advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial |
| Meeting Title: | 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 76 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2015 Dec 8-12 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2016-02-15 |
| Language: | English |
| ACCESSION: | WOS:000375622400065 |
| DOI: | 10.1158/1538-7445.sabcs15-s6-01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: S6-01 -- Source: Wos |
